// App-Quantinova.ai

P219 : Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study

Researchers

Presenter

  • Laura Coates

Principal Investigators

  • Philip Mease

  • Dafna Gladman

  • Filip Van den Bosch

  • Anna Rychlewska-Hanczewska

  • Chantal Tasset

  • Luc Meuleners

  • Mona Trivedi

  • Ying Guo

  • Robin Besuyen

  • Philip Helliwell

Medical Centers

  • Rheumatology, University of Oxford, Oxford, UNITED KINGDOM

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Immunology, University of Toronto, Toronto, ON, CANADA

  • Rheumatology, University of Ghent, Ghent, BELGIUM

  • Rheumatology, ai centrum medyczne sp. z o.o. sp.k, Poznan, POLAND

  • Rheumatology, Galapagos NV, Mechelen, BELGIUM

  • Biostatistics, Galapagos NV, Mechelen, BELGIUM

  • Epidemiology, Gilead Sciences, Foster City, CA

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

Locations

  • United Kingdom

  • United States

  • Canada

  • Belgium

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • II

Study Id's

  • NCT03101670

  • NCT03320876

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved